CTNNB1 and cancer: Besides WNT/Beta-catenin, TGF-beta, and c-Myc signaling, as well as G2/M checkpoint, downregulation of the spliceosome pathway also suggests an anti-cancer activity since splicing is significantly affected by cancer transformation [37,38], and inhibitors of splicing have been developed for cancer treatment [39].